Creating the ideal immunotherapy
Inducing a Broad
Cancer Stem Cells
Vaxil’s Lead Products and Orphan Drug Status
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™ platform is its Immucin™; lead immunotherapy product. After completion of a successful Phase-I/II in 15 multiple myeloma cancer patients, Vaxil’s Immucin™ was granted Orphan Drug Status by the FDA and EMA for that indication.
Immunotherapy has become the most promising field in the fight against cancer. Whereas chemotherapy was once seen as a breakthrough and still utilized successfully in many patients, today’s scientists recognize immunotherapy is the way of the future. Learn More
VAXIL’S PRIMARY PLATFORM GENERATES COMPREHENSIVE IDENTIFICATION, ISOLATION & PRODUCTION OF ANTIGEN-SPECIFIC IMMUNOTHERAPIES Vaxil’s VaxHit™ platform technology combines proprietary algorithms which enable in-silico identification of signal peptides domains and their subsequent use as immunotherapeutic products. The VaxHit™ platform is essentially a launchpad for novel and uniquely targeted immunotherapy products. Learn More